Krystal Biotech (KRYS) Short-term Investments (2018 - 2026)

Krystal Biotech has disclosed Short-term Investments across 9 years of filings, most recently posting $322.1 million for Q1 2026.

• Short-term Investments for Q1 2026 came in at $322.1 million, up 4.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $322.1 million (up 4.55% YoY), and the FY2025 annual result was $331.5 million, up 31.2% from the prior year.
• Short-term Investments came in at $322.1 million for Q1 2026 at Krystal Biotech, down from $331.5 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $338.5 million in Q3 2025 to a low of $165.3 million in Q1 2022.
• The 5-year median for Short-term Investments is $213.8 million (2024), against an average of $238.8 million.
• Across the five-year window, Short-term Investments surged 13147.52% in 2022 and dropped 19.98% in 2023, its largest moves.
• Krystal Biotech's Short-term Investments stood at $217.3 million in 2022, then decreased by 19.98% to $173.8 million in 2023, then surged by 45.33% to $252.7 million in 2024, then soared by 31.2% to $331.5 million in 2025, then declined by 2.83% to $322.1 million in 2026.
• The last three Short-term Investments figures came in at $322.1 million (Q1 2026), $331.5 million (Q4 2025), and $338.5 million (Q3 2025), per Business Quant data.